{"entity":{"id":"nct04585490","kind":"trial","name":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC","aka":[],"tldr":"A phase 3 trial of durvalumab, carboplatin, pemetrexed, paclitaxel / nab-paclitaxel and other drugs in lung cancer, run by Maximilian Diehn, now recruiting.","summary":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC is a phase 3, interventional study registered as NCT04585490 by Maximilian Diehn, with a registry enrolment figure of 48 participants, started 2021-08-25 and due to reach its primary completion in 2026-08. Interventions recorded: Durvalumab; Carboplatin; Pemetrexed; Paclitaxel; Cisplatin; AVENIO ctDNA Surveillance Kit; Tremelimumab. Conditions listed: Non Small Cell Lung Cancer; NSCLC, Stage III; Nsclc. Primary outcome: Change in ctDNA Level Following Chemotherapy. Lung eligibility wording from the registry: \"Histologically- or cytologically-documented NSCLC presenting with locally-advanced, unresectable stage III disease (Version 8 of AJCC Staging Manual) or NSCLC with locoregional recurrence after previous definitive treatment\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04585490","url":"https://clinicaltrials.gov/study/NCT04585490"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["stage-iii-unresectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","imrt-igrt","mrd-testing","platinum"],"targets":[],"drugs":["durvalumab","carboplatin","pemetrexed","paclitaxel","cisplatin","tremelimumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04585490","phase":"3","setting":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC","sponsor":"Maximilian Diehn","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04585490/","neighbours":{"cancer":[{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}